• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Optimal kinetic exposures for classic and candidate antitrypanosomals.经典和候选抗锥虫药物的最佳动力学暴露量。
J Antimicrob Chemother. 2019 Aug 1;74(8):2303-2310. doi: 10.1093/jac/dkz160.
2
In vitro activity of Triclisia patens and some bisbenzylisoquinoline alkaloids against Leishmania donovani and Trypanosoma brucei brucei.非洲防己及一些双苄基异喹啉生物碱对杜氏利什曼原虫和布氏布氏锥虫的体外活性
Phytother Res. 2002 Aug;16(5):432-6. doi: 10.1002/ptr.929.
3
Antiprotozoal and cytotoxic screening of 45 plant extracts from Democratic Republic of Congo.对刚果民主共和国45种植物提取物进行抗寄生虫和细胞毒性筛选。
J Ethnopharmacol. 2008 Feb 12;115(3):409-15. doi: 10.1016/j.jep.2007.10.028. Epub 2007 Dec 18.
4
Evaluation of DL-alpha-difluoromethylornithine against susceptible and drug-resistant Trypanosoma brucei brucei.DL-α-二氟甲基鸟氨酸对敏感及耐药布氏布氏锥虫的评估
Acta Trop. 1991 Jan;48(3):223-32. doi: 10.1016/0001-706x(91)90050-t.
5
Chemotherapeutic approaches to protozoa: kinetoplastida--current level of knowledge and outlook.原生动物的化疗方法:动质体目——当前的知识水平与展望
Parasitol Res. 2001 Sep;87(9):778-80. doi: 10.1007/s004360100404.
6
Pentamidine uptake and resistance in pathogenic protozoa: past, present and future.致病原生动物中喷他脒的摄取与耐药性:过去、现在与未来
Trends Parasitol. 2003 May;19(5):232-9. doi: 10.1016/s1471-4922(03)00069-2.
7
Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites.分析抗癌组蛋白去乙酰化酶抑制剂对疟原虫和锥虫寄生虫的抗寄生虫活性。
Int J Parasitol Drugs Drug Resist. 2015 Jun 20;5(3):117-26. doi: 10.1016/j.ijpddr.2015.05.004. eCollection 2015 Dec.
8
Clomipramine kills Trypanosoma brucei by apoptosis.
Int J Med Microbiol. 2016 Jun;306(4):196-205. doi: 10.1016/j.ijmm.2016.03.009. Epub 2016 Apr 6.
9
Studies on the efficacy of DL-alpha-difluoromethylornithine (DFMO) associated with bleomycin and suramin for treatment of mice infected with metacyclic forms of Trypanosoma brucei brucei.
Vet Res Commun. 1987;11(3):271-4. doi: 10.1007/BF00570924.
10
QSAR analysis for 6-arylpyrazine-2-carboxamides as Trypanosoma brucei inhibitors.作为布氏锥虫抑制剂的6-芳基吡嗪-2-甲酰胺的定量构效关系分析
SAR QSAR Environ Res. 2017 Feb;28(2):165-177. doi: 10.1080/1062936X.2017.1292407.

引用本文的文献

1
Prophylactic low-dose, bi-weekly benznidazole treatment fails to prevent Trypanosoma cruzi infection in dogs under intense transmission pressure.在高强度传播压力下,预防低剂量、双周贝那唑治疗未能预防犬感染克氏锥虫。
PLoS Negl Trop Dis. 2022 Oct 31;16(10):e0010688. doi: 10.1371/journal.pntd.0010688. eCollection 2022 Oct.
2
New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia.新型抗恰加斯病化疗方案和生物标志物:TESEO 研究的原理和设计,一项在玻利维亚多民族国开展的开放标签、随机、前瞻性、2 期临床试验。
BMJ Open. 2021 Dec 31;11(12):e052897. doi: 10.1136/bmjopen-2021-052897.
3
Non-invasive monitoring of drug action: A new live in vitro assay design for Chagas' disease drug discovery.非侵入性药物作用监测:一种用于查加斯病药物发现的新型活体体外检测设计。
PLoS Negl Trop Dis. 2020 Jul 27;14(7):e0008487. doi: 10.1371/journal.pntd.0008487. eCollection 2020 Jul.
4
Investigation of pyrimidine nucleoside analogues as chemical probes to assess compound effects on the proliferation of Trypanosoma cruzi intracellular parasites.嘧啶核苷类似物作为化学探针评估化合物对 Trypanosoma cruzi 内寄生虫增殖影响的研究。
PLoS Negl Trop Dis. 2020 Mar 12;14(3):e0008068. doi: 10.1371/journal.pntd.0008068. eCollection 2020 Mar.
5
Kinetic Driver of Antibacterial Drugs against and Implications for Clinical Dosing.抗菌药物对 的动力学驱动及其对临床给药的意义。
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.00416-19. Print 2019 Nov.

本文引用的文献

1
The Long Wait for a New Drug for Human African Trypanosomiasis.人类非洲锥虫病新药研发漫长路漫漫。
Trends Parasitol. 2018 Oct;34(10):818-827. doi: 10.1016/j.pt.2018.08.006. Epub 2018 Sep 1.
2
Model System Identifies Kinetic Driver of Hsp90 Inhibitor Activity against African Trypanosomes and Plasmodium falciparum.模型系统鉴定 Hsp90 抑制剂对非洲锥虫和疟原虫活性的动力学驱动因素。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00056-18. Print 2018 Aug.
3
Fexinidazole: A New Drug for African Sleeping Sickness on the Horizon.非昔硝唑:一种有望用于治疗非洲昏睡病的新药。
Trends Parasitol. 2018 Mar;34(3):178-179. doi: 10.1016/j.pt.2017.12.002. Epub 2017 Dec 20.
4
Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.口服非昔硝唑治疗晚期非洲冈比亚锥虫布氏锥虫病:一项关键性多中心、随机、非劣效性试验。
Lancet. 2018 Jan 13;391(10116):144-154. doi: 10.1016/S0140-6736(17)32758-7. Epub 2017 Nov 4.
5
Pre-clinical in vitro infection models.临床前体外感染模型。
Curr Opin Pharmacol. 2017 Oct;36:100-106. doi: 10.1016/j.coph.2017.09.011. Epub 2017 Oct 14.
6
Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis.在感染人类非洲锥虫病的小鼠模型中,非昔硝唑及其代谢物的剂量依赖性效应和药代动力学。
Int J Antimicrob Agents. 2017 Aug;50(2):203-209. doi: 10.1016/j.ijantimicag.2017.01.038. Epub 2017 May 25.
7
Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.抗真菌药物研发的药效学:一种加速、风险最小化及因果关系论证的方法。
J Antimicrob Chemother. 2016 Nov;71(11):3008-3019. doi: 10.1093/jac/dkw298. Epub 2016 Aug 5.
8
Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.测定新型口服药物非昔硝唑治疗非洲人类锥虫病的最佳剂量方案:人体首次研究。
Clin Pharmacokinet. 2014 Jun;53(6):565-80. doi: 10.1007/s40262-014-0136-3.
9
Model system to define pharmacokinetic requirements for antimalarial drug efficacy.定义抗疟药物疗效药代动力学要求的模型系统。
Sci Transl Med. 2013 Oct 2;5(205):205ra135. doi: 10.1126/scitranslmed.3006684.
10
Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis.利用未结合的靶组织暴露作为基于处置的先导优化苯并硼杂环化合物治疗 2 期人类非洲锥虫病的理由的药代动力学和药效学。
Parasitology. 2014 Jan;141(1):104-18. doi: 10.1017/S003118201300098X. Epub 2013 Sep 5.

经典和候选抗锥虫药物的最佳动力学暴露量。

Optimal kinetic exposures for classic and candidate antitrypanosomals.

机构信息

Division of Clinical Pharmacology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

出版信息

J Antimicrob Chemother. 2019 Aug 1;74(8):2303-2310. doi: 10.1093/jac/dkz160.

DOI:10.1093/jac/dkz160
PMID:31093674
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6640303/
Abstract

OBJECTIVES

Efficacy is determined not only by size, but also by shape, of drug exposure. Here the critical importance of the temporal pattern of drug concentrations (pharmacokinetic profile) is examined for antitrypanosomals in vitro.

METHODS

An in vitro hollow-fibre cartridge system was used to study contrasting drug profiles with four clinically used agents and two experimental candidates against the deadly parasite Trypanosoma brucei. Artificial kinetics were employed intentionally to favour either high peak concentration or sustained duration of drug.

RESULTS

Changing the shape of drug exposure significantly impacted drug efficacy. Suramin, melarsoprol and pentamidine were concentration-driven and therefore more efficacious when applied as short-lived high peaks. In contrast, difluoromethylornithine (DFMO) was time-driven, and therefore maximally effective as a constant infusion. Kinetic preference was robust over a wide range of drug exposures. Promising clinical candidates SCYX-7158 (acoziborole) and fexinidazole (parent and sulfone) were concentration-driven, suggesting optimal clinical regimens would involve relatively high but intermittent dosing.

CONCLUSIONS

Antitrypanosomals have an intrinsic pharmacokinetic driver for optimal efficacy, with important implications for clinical management and future candidate development.

摘要

目的

药物暴露的效果不仅取决于其大小,还取决于其形状。本研究旨在探讨体外抗锥虫药物的药物浓度(药代动力学特征)时间模式的重要性。

方法

采用中空纤维筒式系统,用四种临床应用药物和两种实验候选药物对致命寄生虫布氏锥虫进行对比药物特征研究。人为改变动力学特征,有利于药物浓度峰值高或药物持续时间长。

结果

改变药物暴露的形状显著影响药物疗效。苏拉明、美拉胂醇和喷他脒是浓度依赖性的,因此作为短暂的高浓度时更有效。相比之下,二氟甲基鸟氨酸(DFMO)是时间依赖性的,因此作为持续输注时效果最佳。在广泛的药物暴露范围内,动力学偏好是稳健的。有前途的临床候选药物 SCYX-7158(阿卡波洛尔)和非奈硝唑(母体和砜)是浓度依赖性的,这表明最佳的临床方案将涉及相对较高但间歇性的给药。

结论

抗锥虫药物具有内在的药代动力学驱动因素,以达到最佳疗效,这对临床管理和未来候选药物的开发具有重要意义。